The HTRA1 Knockout KYSE-30 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human KYSE-30 esophageal squamous cell carcinoma line. This product provides a powerful loss-of-function model for the HTRA1 gene, which encodes a serine protease with established tumor suppressor functions. The polyclonal nature of the knockout pool allows researchers to study gene disruption effects across a heterogeneous cell population, avoiding clonal selection biases. Engineered through CRISPR/Cas9-mediated gene disruption, these cells are a versatile tool for dissecting HTRA1’s role in TGF-?? signaling and cancer biology.
The KYSE-30 host cell line originates from a poorly differentiated human esophageal squamous cell carcinoma, serving as a well-characterized model for esophageal epithelial cancer. These cells maintain key properties of malignant transformation, including aberrant proliferation and migratory capacity. As an established esophageal cancer cell line, KYSE-30 offers a clinically relevant background for exploring tumor suppressor mechanisms and oncogenic signaling pathways implicated in esophageal carcinogenesis.
HTRA1 encodes a secreted serine protease that negatively modulates TGF-?? signaling by cleaving and inactivating type II and type III TGF-?? receptors. This proteolytic attenuation suppresses SMAD2/3 phosphorylation and subsequent SMAD4-mediated transcriptional responses, leading to reduced cell proliferation and migration. Beyond TGF-??, HTRA1 impacts Wnt/??-catenin, MAPK/ERK, and PI3K/AKT pathways through interactions with fibronectin, amyloid precursor protein, and PDZ domain-containing ligands. The HTRA1 gene is itself regulated by TGF-??, oxidative stress, and the p53 tumor suppressor, positioning it at a critical node in growth-inhibitory networks. By limiting TGF-?? receptor availability, HTRA1 serves as a molecular brake on pro-oncogenic cascades.
In the KYSE-30 esophageal carcinoma context, HTRA1 functions as a tumor suppressor, and its loss is anticipated to enhance canonical TGF-??/SMAD signaling. This may promote epithelial-mesenchymal transition, invasion, and metastatic traits. The polyclonal knockout model enables dissection of HTRA1’s growth-suppressive effects and its influence on the tumor microenvironment. The population-based knockout better reflects tumor heterogeneity compared to monoclonal derivatives, facilitating more physiologically relevant functional studies.
Key research applications include mechanistic investigations of TGF-?? signaling in esophageal squamous cell carcinoma, assessment of tumor suppressor gene activity, and screening of modulators targeting the HTRA1/TGF-?? axis. Compatible assays include Western blotting for phospho-SMAD2/3, RT-qPCR analysis of TGF-?? target genes (e.g., SERPINE1, CTGF), and phenotypic readouts for proliferation, migration, and invasion. Transcriptomic profiling via RNA-seq can further uncover global expression changes upon HTRA1 loss. For additional technical information, please contact Ascent Research.
